Activation of Soluble Adenylyl Cyclase as a Novel Therapeutic Strategy for the Treatment of Age-Related Neurodegenerative Disorders

激活可溶性腺苷酸环化酶作为治疗年龄相关神经退行性疾病的新治疗策略

• 批准号: 10443843
• 负责人: Thomas Rossetti
• 金额: $ 3.74万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-11 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10443843
• 关键词: Acids; Adenosine Triphosphate; Adenylate Cyclase; Affect; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease pathology; Alzheimer' s disease patient; Amyloid; Autophagocytosis; Biological; Biological Assay; Biological Sciences; Biology; Cell Aging; Cell model; Cells; Chemicals; Cyclic AMP; Cyclization; Defect; Degradation Pathway; Disease; Disease Progression; Environment; Enzyme-Linked Immunosorbent Assay; Exhibits; FDA approved; Fibroblasts; Functional disorder; Genetic; Hydrolase; Immune; In Vitro; Individual; Knock-out; Label; Length; Libraries; Life Expectancy; LysoTracker; Lysosomes; Mammalian Cell; Measures; Methods; Microglia; Modeling; Neurodegenerative Disorders; Organelles; Parkinson Disease; Pathogenesis; Pathologic; Patients; Pharmacology; Phenotype; Physiological; Physiological Processes; Play; Population; Protein Isoforms; Public Health; Research; Role; Second Messenger Systems; Signal Transduction; Signal Transduction Pathway; Specificity; Testing; Western Blotting; age related; age related neurodegeneration; aging population; alkalinity; base; brain cell; cell age; cell type; cellular engineering; effective therapy; experimental study; familial Alzheimer disease; high throughput screening; human old age (65+); in vitro Assay; inhibitor; misfolded protein; mutant; novel; novel strategies; novel therapeutic intervention; overexpression; presenilin-1; protein aggregation; protein degradation; small molecule; therapeutically effective; tool; treatment strategy

Project Summary/Abstract The worldwide population of individuals over the age of 65 is continuing to grow and is expected to double over the next 30 years. Due to this increase, an associated rise in age-related neurodegenerative diseases (NDs), such as Alzheimer’s (AD) and Parkinson’s disease, has been observed. Despite decades of research, there are currently no FDA-approved therapies that can stop or reverse disease progression. The accumulation of misfolded protein aggregates is a common feature of age-related NDs and is thought to be heavily involved in the pathophysiology of the diseases. Proteins aggregates can be cleared from the cell through autophagy, one of the major biological degradation pathways. Protein aggregates are degraded in the final step of autophagy, where they are delivered to cellular organelles known as lysosomes. Lysosomes maintain an acidic pH between 4-5 to maintain an optimal environment for acid hydrolases. In aging cells and in a cellular model of AD, lysosomes become less acidic, their hydrolases become less active and, as a result, there is a decrease in degradation through autophagy (i.e., autophagic flux) and an accumulation of undigested materials. In models of AD pathology, re-acidification of lysosomal pH, via addition of exogenous cAMP, reversed this phenotype. In line with these findings, we have shown that cAMP generated from a cytosolic adenylyl cyclase isoform, known as Soluble Adenylyl Cyclase (sAC), promotes lysosomal acidification. In addition, cells that do not express sAC show decreased autophagic flux. This, and other, physiological roles of sAC have been determined via the use of inhibitors and various genetic tools that were developed to study sAC biology. However, the “toolbox” that is currently used to study sAC is lacking a key component: a pharmacological activator of sAC. To identify a sAC activator, we conducted a high-throughput screen of 400,000 chemically diverse compounds. From this library we discovered 13 presumptive sAC activators. In this proposal, I describe the in vitro and cell-based assays that I will use to confirm, characterize, and further develop these 13 compounds as “first-of-their kind” small molecule activators selective for sAC. Using the newly discovered sAC activators, I will test the hypothesis that stimulating sAC can enhance lysosomal acidification and stimulate autophagy, and as a result, decrease accumulation of protein aggregates. If successful, these studies will validate small molecule sAC activators as a potential novel therapeutic strategy to treat neurodegenerative disorders.

项目总结/文摘

项目成果

On-demand male contraception via acute inhibition of soluble adenylyl cyclase.

• DOI: 10.1038/s41467-023-36119-6
• 发表时间: 2023-02-14
• 期刊: NATURE COMMUNICATIONS
• 影响因子: 16.6
• 作者: Balbach, Melanie;Rossetti, Thomas;Ferreira, Jacob;Ghanem, Lubna;Ritagliati, Carla;Myers, Robert W. W.;Huggins, David J. J.;Steegborn, Clemens;Miranda, Ileana C. C.;Meinke, Peter T. T.;Buck, Jochen;Levin, Lonny R. R.
• 通讯作者: Levin, Lonny R. R.